venBio
1700 Owens Street, Suite 595
San Francisco
California
94158
United States
Tel: 415-800-0800
Website: http://www.venbio.com/
Email: info@venbio.com
15 articles about venBio
-
Money on the Move: June 2-8
6/9/2021
Things are warming up quickly this summer for life sciences investors. Here’s who’s coming in hot with cash this week. -
venBio Raises $550 Million Venture Capital Fund Focused on Life Sciences
6/3/2021
venBio today announced the closing of venBio Global Strategic Fund IV, LP (“venBio Fund IV”), its fourth life sciences venture capital fund, exceeding its target and closing on approximately $550 million in capital commitments in an oversubscribed fundraise.
-
venBio Global Strategic Fund IV will invest primarily in drug companies focused on developing therapies for unmet medical needs.
-
The capital was raised from existing and new investors, including a broad range of institutional investors comprised of pharmaceutical companies, corporate pensions, financial institutions, endowments and foundations, family offices and funds-of-funds.
-
Ligand Enters into Agreement with venBio to Make Worldwide OmniAb® Platform License Accessible to Portfolio Companies
3/30/2018
venBio’s portfolio companies will be able to use the full OmniAb platform including OmniRat®, OmniMouse®, OmniFlic® and OmniChicken™ to discover fully human mono- and bispecific antibodies.
-
A Win for venBio as Judge Hits Pause on Immunomedics's $2 Billion Deal With Seattle Genetics
3/13/2017
-
venBio Encourages Stockholders To Vote For Change
3/3/2017
-
Immunomedics Outlines Revised Settlement Offer Rejected By venBio; Announces Actions That Are In The Best Interests Of All Stockholders
3/2/2017
-
venBio Sends Letter To Immunomedics Stockholders
2/22/2017
-
Why Immunomedics' $2 Billion Deal With Seattle Genetics Has venBio Ticked Off and Red-Faced
2/13/2017
-
venBio Comments On Immunomedics Partnership Announcement
2/13/2017
-
venBio Calls On Immunomedics Stockholders To Support Meaningful Change
1/30/2017
-
venBio Release: Company Releases Presentation Detailing Urgent Case For Change At Immunomedics
1/26/2017
-
venBio Release: Company Sends Letter To Immunomedics Stockholders
1/11/2017
-
Bay Area VC Firm venBio Closes $315 Million Life Sciences Fund
5/6/2016